CD8A and hemophagocytic syndrome: Additionally, hemophagocytic lymphohistiocytosis, a fatal complication of SLE, primarily driven by uncontrolled activation of pathogenic CD8+ T cells, has been shown to be responsive to ruxolitinib in a case report (33).